nach oben

Erschienen in:

17.02.2018 | Original Article

Hyperirisinemia is independently associated with subclinical hypothyroidism: correlations with cardiometabolic biomarkers and risk factors

verfasst von: Theodora Stratigou, Maria Dalamaga, Georgios Antonakos, Ioanna Marinou, Evaggelos Vogiatzakis, Gerasimos Socrates Christodoulatos, Irene Karampela, Athanasios G. Papavassiliou

Erschienen in: Endocrine | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Irisin, a newly discovered adipo-myokine, is implicated in the modulation of the adipose phenotype, increasing energy expenditure and ameliorating systemic metabolism. Our aim was to investigate circulating irisin in subclinical hypothyroidism (SH) and study its associations with cardiometabolic risk factors.

Methods

In a large case–control study, serum irisin, insulin resistance and lipid parameters, classic adipokines, inflammatory and hepatic biomarkers, and cardiovascular risk factors were determined in 120 consecutive patients with SH and 120 healthy controls matched on age, gender, and date of blood draw. Sixteen patients with SH received L-T4 treatment and, after 6 months, serum irisin and other biomarkers were assessed.

Results

SH cases exhibited significantly higher circulating irisin than controls (p < 0.001). In all participants, irisin was positively associated with TSH, anti-TG, HOMA-IR, C-peptide, lipid and inflammatory biomarkers, leptin, and cardiovascular risk factors, including Framigham score and apolipoprotein B/apolipoprotein A-I. Irisin was negatively correlated with adiponectin, HDL-C, and thyroid hormones. Serum irisin was independently associated with SH, above and beyond body mass index and cardiometabolic factors (p = 0.02). TSH was an independent predictor of circulating irisin (p = 0.003). L-T4 therapy did not reverse considerably the hyperirisinemic status in treated SH patients (p = 0.09).

Conclusions

Irisin may represent an adipo-myokine counterbalancing a potential, gradual deterioration of lipid metabolism and insulin sensitivity in SH as well as reflecting a protective compensatory mechanism against oxidative muscle and thyroid cell stress. More mechanistic and prospective studies shedding light on the pathogenetic role of irisin in SH are needed to confirm and extend these data.

R.P. Peeters, Subclinical hypothyroidism. N. Engl. J. Med. 377(14), 1404 (2017). https://doi.org/10.1056/NEJMc1709853 CrossRefPubMed

A.P. Delitala, G. Fanciulli, M. Maioli, G. Delitala, Subclinical hypothyroidism, lipid metabolism and cardiovascular disease. Eur. J. Intern. Med. 38, 17–24 (2017). https://doi.org/10.1016/j.ejim.2016.12.015 CrossRefPubMed

A.E. Hak, H.A. Pols, T.J. Visser, H.A. Drexhage, A. Hofman, J.C. Witteman, Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann. Intern. Med. 132(4), 270–278 (2000)CrossRefPubMed

D. Liu, F. Jiang, Z. Shan, B. Wang, J. Wang, Y. Lai, Y. Chen, M. Li, H. Liu, C. Li, H. Xue, N. Li, J. Yu, L. Shi, X. Bai, X. Hou, L. Zhu, L. Lu, S. Wang, Q. Xing, W. Teng, A cross-sectional survey of relationship between serum TSH level and blood pressure. J. Hum. Hypertens. 24(2), 134–138 (2010). https://doi.org/10.1038/jhh.2009.44 CrossRefPubMed

N. Rodondi, W.P. den Elzen, D.C. Bauer, A.R. Cappola, S. Razvi, J.P. Walsh, B.O. Asvold, G. Iervasi, M. Imaizumi, T.H. Collet, A. Bremner, P. Maisonneuve, J.A. Sgarbi, K.T. Khaw, M.P. Vanderpump, A.B. Newman, J. Cornuz, J.A. Franklyn, R.G. Westendorp, E. Vittinghoff, J. Gussekloo, Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 304(12), 1365–1374 (2010). https://doi.org/10.1001/jama.2010.1361 CrossRefPubMedPubMedCentral

J.Y. Huh, G. Panagiotou, V. Mougios, M. Brinkoetter, M.T. Vamvini, B.E. Schneider, C.S. Mantzoros, FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 61(12), 1725–1738 (2012). https://doi.org/10.1016/j.metabol.2012.09.002 CrossRefPubMedPubMedCentral

G. Panagiotou, K. Pazaitou-Panayiotou, S.A. Paschou, D. Komninou, N. Kalogeris, A. Vryonidou, C.S. Mantzoros, Changes in thyroid hormone levels within the normal and/or subclinical hyper- or hypothyroid range do not affect circulating irisin levels in humans. Thyroid 26(8), 1039–1045 (2016). https://doi.org/10.1089/thy.2016.0098 CrossRefPubMed

P. Bostrom, J. Wu, M.P. Jedrychowski, A. Korde, L. Ye, J.C. Lo, K.A. Rasbach, E.A. Bostrom, J.H. Choi, J.Z. Long, S. Kajimura, M.C. Zingaretti, B.F. Vind, H. Tu, S. Cinti, K. Hojlund, S.P. Gygi, B.M. Spiegelman, A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481(7382), 463–468 (2012). https://doi.org/10.1038/nature10777 CrossRefPubMedPubMedCentral

K. Panati, Y. Suneetha, V.R. Narala, Irisin/FNDC5—an updated review. Eur. Rev. Med. Pharmacol. Sci. 20(4), 689–697 (2016)PubMed

10.

K.I. Stanford, R.J. Middelbeek, K.L. Townsend, D. An, E.B. Nygaard, K.M. Hitchcox, K.R. Markan, K. Nakano, M.F. Hirshman, Y.H. Tseng, L.J. Goodyear, Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J. Clin. Invest. 123(1), 215–223 (2013). https://doi.org/10.1172/jci62308 CrossRefPubMed

11.

J.A. Timmons, B.K. Pedersen, The importance of brown adipose tissue. N. Engl. J. Med. 361(4), 415–416 (2009). https://doi.org/10.1056/NEJMc091009. author reply 418-421CrossRefPubMed

12.

T. Hofmann, U. Elbelt, A. Stengel, Irisin as a muscle-derived hormone stimulating thermogenesis—a critical update. Peptides 54, 89–100 (2014). https://doi.org/10.1016/j.peptides.2014.01.016 CrossRefPubMed

13.

K.N. Aronis, M. Moreno, S.A. Polyzos, J.M. Moreno-Navarrete, W. Ricart, E. Delgado, J. de la Hera, A. Sahin-Efe, J.P. Chamberland, R. Berman, A. Spiro 3rd, P. Vokonas, J.M. Fernandez-Real, C.S. Mantzoros, Circulating irisin levels and coronary heart disease: association with future acute coronary syndrome and major adverse cardiovascular events. Int. J. Obes. 39(1), 156–161 (2015). https://doi.org/10.1038/ijo.2014.101 CrossRef

14.

K.H. Park, L. Zaichenko, M. Brinkoetter, B. Thakkar, A. Sahin-Efe, K.E. Joung, M.A. Tsoukas, E.V. Geladari, J.Y. Huh, F. Dincer, C.R. Davis, J.A. Crowell, C.S. Mantzoros, Circulating irisin in relation to insulin resistance and the metabolic syndrome. J. Clin. Endocrinol. Metab. 98(12), 4899–4907 (2013). https://doi.org/10.1210/jc.2013-2373 CrossRefPubMed

15.

N. Perakakis, G.A. Triantafyllou, J.M. Fernandez-Real, J.Y. Huh, K.H. Park, J. Seufert, C.S. Mantzoros, Physiology and role of irisin in glucose homeostasis. Nat. Rev. Endocrinol. 13(6), 324–337 (2017). https://doi.org/10.1038/nrendo.2016.221 CrossRefPubMedPubMedCentral

16.

S.A. Polyzos, A.D. Anastasilakis, Z.A. Efstathiadou, P. Makras, N. Perakakis, J. Kountouras, C.S. Mantzoros, Irisin in metabolic diseases. Endocrine (2017). https://doi.org/10.1007/s12020-017-1476-1

17.

I. Ates, M. Altay, C. Topcuoglu, F.M. Yilmaz, Circulating levels of irisin is elevated in hypothyroidism, a case-control study. Arch. Endocrinol. Metab. 60(2), 95–100 (2016). https://doi.org/10.1590/2359-3997000000077 CrossRefPubMed

18.

E. Atici, R. Mogulkoc, A.K. Baltaci, E. Menevse, Both hypothyroidism and hyperthyroidism increase plasma irisin levels in rats. Horm. Mol. Biol. Clin. Investig. (2017). https://doi.org/10.1515/hmbci-2017-0054

19.

M. Ruchala, A. Zybek, E. Szczepanek-Parulska, Serum irisin levels and thyroid function—newly discovered association. Peptides 60, 51–55 (2014). https://doi.org/10.1016/j.peptides.2014.07.021 CrossRefPubMed

20.

D.M. Samy, C.A. Ismail, R.A. Nassra, Circulating irisin concentrations in rat models of thyroid dysfunction—effect of exercise. Metabolism 64(7), 804–813 (2015). https://doi.org/10.1016/j.metabol.2015.01.001 CrossRefPubMed

21.

A. Zybek-Kocik, N. Sawicka-Gutaj, E. Szczepanek-Parulska, M. Andrusiewicz, J. Waligorska-Stachura, P. Bialas, T. Krauze, P. Guzik, J. Skrobisz, M. Ruchala, The association between irisin and muscle metabolism in different thyroid disorders. Clin. Endocrinol. (2017). https://doi.org/10.1111/cen.13527

22.

A. Zybek-Kocik, N. Sawicka-Gutaj, E. Wrotkowska, J. Sowinski, M. Ruchala, Time-dependent irisin concentration changes in patients affected by overt hypothyroidism. Endokrynol. Pol. 67(5), 476–480 (2016). https://doi.org/10.5603/EP.a2016.0030 CrossRefPubMed

23.

M.M. Yalcin, M. Akturk, Y. Tohma, E.T. Cerit, A.E. Altinova, E. Arslan, I. Yetkin, F.B. Toruner, Irisin and myostatin levels in patients with Graves’ disease. Arch. Med. Res. 47(6), 471–475 (2016). https://doi.org/10.1016/j.arcmed.2016.11.002 CrossRefPubMed

24.

P. Deurenberg, J.A. Weststrate, J.C. Seidell, Body mass index as a measure of body fatness: age- and sex-specific prediction formulas. Br. J. Nutr. 65(2), 105–114 (1991)CrossRefPubMed

25.

R.B. D’Agostino Sr., R.S. Vasan, M.J. Pencina, P.A. Wolf, M. Cobain, J.M. Massaro, W.B. Kannel, General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117(6), 743–753 (2008). https://doi.org/10.1161/circulationaha.107.699579 CrossRefPubMed

26.

I. Karampela, E. Kandri, G. Antonakos, E. Vogiatzakis, G.S. Christodoulatos, A. Nikolaidou, G. Dimopoulos, A. Armaganidis, M. Dalamaga, Kinetics of circulating fetuin-A may predict mortality independently from adiponectin, high molecular weight adiponectin and prognostic factors in critically ill patients with sepsis: a prospective study. J. Crit. Care 41, 78–85 (2017). https://doi.org/10.1016/j.jcrc.2017.05.004 CrossRefPubMed

27.

M. Dalamaga, K. Karmaniolas, E. Papadavid, N. Pelekanos, G. Sotiropoulos, A. Lekka, Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters. Menopause 18(11), 1198–1204 (2011). https://doi.org/10.1097/gme.0b013e31821e21f5 CrossRefPubMed

28.

M. Dalamaga, G. Sotiropoulos, K. Karmaniolas, N. Pelekanos, E. Papadavid, A. Lekka, Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters. Clin. Biochem. 46(7–8), 584–590 (2013). https://doi.org/10.1016/j.clinbiochem.2013.01.001 CrossRefPubMed

29.

M. Dalamaga, K. Karmaniolas, A. Nikolaidou, J. Chamberland, A. Hsi, A. Dionyssiou-Asteriou, C.S. Mantzoros, Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system. Eur. J. Cancer 44(12), 1744–1753 (2008). https://doi.org/10.1016/j.ejca.2008.04.015 CrossRefPubMed

30.

S.A. Polyzos, H. Mathew, C.S. Mantzoros, Irisin: a true, circulating hormone. Metabolism 64(12), 1611–1618 (2015). https://doi.org/10.1016/j.metabol.2015.09.001 CrossRefPubMed

31.

F. Cook, Advanced Methods in Clinical Epidemiology. (Harvard School of Public Health, Boston, MA, 2000)

32.

J.V. Hennessey, R. Espaillat, Subclinical hypothyroidism: a historical view and shifting prevalence. Int. J. Clin. Pract. 69(7), 771–782 (2015). https://doi.org/10.1111/ijcp.12619 CrossRefPubMedPubMedCentral

33.

I. Legakis, M. Manousaki, S. Detsi, D. Nikita, Thyroid function and prevalence of anti-thyroperoxidase (TPO) and anti-thyroglobulin (Tg) antibodies in outpatients hospital setting in an area with sufficient iodine intake: influences of age and sex. Acta Med. Iran. 51(1), 25–34 (2013)PubMed

34.

A.C. Bianco, E.A. McAninch, The role of thyroid hormone and brown adipose tissue in energy homoeostasis. Lancet Diabetes Endocrinol. 1(3), 250–258 (2013). https://doi.org/10.1016/s2213-8587(13)70069-x CrossRefPubMedPubMedCentral

35.

M.S. Draman, M. Stechman, D. Scott-Coombes, C.M. Dayan, D.A. Rees, M. Ludgate, L. Zhang, The role of thyrotropin receptor activation in adipogenesis and modulation of fat phenotype. Front. Endocrinol. 8, 83 (2017). https://doi.org/10.3389/fendo.2017.00083 CrossRef

36.

C. Lapa, Y. Maya, M. Wagner, P. Arias-Loza, R.A. Werner, K. Herrmann, T. Higuchi, Activation of brown adipose tissue in hypothyroidism. Ann. Med. 47(7), 538–545 (2015). https://doi.org/10.3109/07853890.2015.1085126 CrossRefPubMed

37.

S. Ellefsen, O. Vikmoen, G. Slettalokken, J.E. Whist, H. Nygaard, I. Hollan, I. Rauk, G. Vegge, T.A. Strand, T. Raastad, B.R. Ronnestad, Irisin and FNDC5: effects of 12-week strength training, and relations to muscle phenotype and body mass composition in untrained women. Eur. J. Appl. Physiol. 114(9), 1875–1888 (2014). https://doi.org/10.1007/s00421-014-2922-x CrossRefPubMed

38.

H.S. Moon, M. Dalamaga, S.Y. Kim, S.A. Polyzos, O.P. Hamnvik, F. Magkos, J. Paruthi, C.S. Mantzoros, Leptin’s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr. Rev. 34(3), 377–412 (2013). https://doi.org/10.1210/er.2012-1053 CrossRefPubMedPubMedCentral

39.

M. Dalamaga, S.H. Chou, K. Shields, P. Papageorgiou, S.A. Polyzos, C.S. Mantzoros, Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives. Cell Metab. 18(1), 29–42 (2013). https://doi.org/10.1016/j.cmet.2013.05.010 CrossRefPubMed

40.

M.D. Roberts, D.S. Bayless, J.M. Company, N.T. Jenkins, J. Padilla, T.E. Childs, J.S. Martin, V.J. Dalbo, F.W. Booth, R.S. Rector, M.H. Laughlin, Elevated skeletal muscle irisin precursor FNDC5 mRNA in obese OLETF rats. Metabolism 62(8), 1052–1056 (2013). https://doi.org/10.1016/j.metabol.2013.02.002 CrossRefPubMedPubMedCentral

41.

S. Qiu, X. Cai, H. Yin, M. Zugel, Z. Sun, J.M. Steinacker, U. Schumann, Association between circulating irisin and insulin resistance in non-diabetic adults: a meta-analysis. Metabolism 65(6), 825–834 (2016). https://doi.org/10.1016/j.metabol.2016.02.006 CrossRefPubMed

42.

F. Sanchis-Gomar, C. Perez-Quilis, The p38-PGC-1alpha-irisin-betatrophin axis: exploring new pathways in insulin resistance. Adipocyte 3(1), 67–68 (2014). https://doi.org/10.4161/adip.27370 CrossRefPubMed

43.

J.Y. Huh, C.S. Mantzoros, Irisin physiology, oxidative stress, and thyroid dysfunction: what next? Metabolism 64(7), 765–767 (2015). https://doi.org/10.1016/j.metabol.2015.02.009 CrossRefPubMed

44.

I. Gouni-Berthold, H.K. Berthold, J.Y. Huh, R. Berman, N. Spenrath, W. Krone, C.S. Mantzoros, Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo. PLoS One 8(9), e72858 (2013). https://doi.org/10.1371/journal.pone.0072858 CrossRefPubMedPubMedCentral

45.

I.M. Abreu, E. Lau, B. de Sousa Pinto, D. Carvalho, Subclinical hypothyroidism: to treat or not to treat, that is the question! A systematic review with meta-analysis on lipid profile. Endocr. Connect. 6(3), 188–199 (2017). https://doi.org/10.1530/ec-17-0028 CrossRefPubMedPubMedCentral

Titel: Hyperirisinemia is independently associated with subclinical hypothyroidism: correlations with cardiometabolic biomarkers and risk factors
verfasst von: Theodora Stratigou
Maria Dalamaga
Georgios Antonakos
Ioanna Marinou
Evaggelos Vogiatzakis
Gerasimos Socrates Christodoulatos
Irene Karampela
Athanasios G. Papavassiliou
Publikationsdatum: 17.02.2018
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2018
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-018-1550-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

20.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Hyperirisinemia is independently associated with subclinical hypothyroidism: correlations with cardiometabolic biomarkers and risk factors

Abstract

Purpose

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis

Kisspeptin and LH pulsatile temporal coupling in PCOS patients

Predictivity of clinical, laboratory and imaging findings in diagnostic definition of palpable thyroid nodules. A multicenter prospective study

Influence of body mass index in anti-Müllerian hormone levels in 951 non-polycystic ovarian syndrome women followed at a reproductive medicine unit

Thyroid cancer-related bone metastases: increasingly good prospects for treatment

Glucocorticoid-induced osteoporosis: an update

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Innere Medizin